OTCM
ORGS
Market cap3mUSD
Oct 08, Last price
0.35USD
1D
0.00%
1Q
-5.41%
Jan 2017
-88.71%
IPO
-97.67%
Name
Orgenesis Inc
Chart & performance
P/E
—
P/S
6.47
EPS
—
Div yield, %
—
Shrs. gr., 5y
16.75%
Rev. gr., 5y
-50.94%
Revenues
530k
-98.53%
Net income
-55m
L+271.82%
CFO
-15m
L-40.47%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.
Key people
Vered Caplan
Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc. · since 2016
Sarah Ferber
Chief Scientific Officer · since 2012
Chief Financial Officer, Treasurer, Secretary · since 2014
Yaron Adler
Director · since 2012
Director · since 2013
Guy Yachin
Director · since 2012
Headquarters & legal address
C/O Business Filings Incorporated
701 South Carson Street
Suite 200
Carson City, NV 89701
US
701 South Carson Street
Suite 200
Carson City, NV 89701
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑11 | 2017‑12 | 2016‑11 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||